Despite the approval of alpelisib that the FDA approved alongside the Therascreen PIK3CA mutation assay as a companion diagnostic, the increasing number of clinically relevant molecular alterations able to select PIK3CA-mutated breast cancer patients escalates the need for highly performant molecular testing methods [10]. Here, PIK3CA is linked to breast carcinoma.